The rapporteur Member State prepared a draft renewal assessment report in consultation with the co-rapporteur Member State and submitted it to the Authority and the Commission on 6 March 2018. In its draft renewal assessment report, the rapporteur Member State proposed that the approval of clofentezine could only be renewed if the applicant submitted additional data to further address certain issues during the subsequent peer review process.
Recital 6, Regulation (EU) 2023/2456
In force